Thiazolidinediones may protect diabetics from Parkinson's disease

The researchers performed a literature search from inception to until 30 September 2019. All real-world evidence studies assessing the use of TZD class of drugs and the risk of PD in people with diabetes were included. The quality of the studies was evaluated using the Newcastle-Ottawa scale.

The primary outcome was the pooled hazard ratio (HR) of PD among type 2 DM TZD users as compared with TZD non-users in people with diabetes. 

A total of 4 retrospective cohort studies with 312,924 participants with T2D, including 66,129 TZD users, were included. The participants' mean age and follow-up duration were 66.23 ± 9.59 years and 5.25 years (2.97–7.9 years), respectively. 

"This meta-analysis demonstrates a potential neuroprotective effect of TZD for PD risk in the population with diabetes," concluded the authors. 

The study, "Thiazolidinedione use is associated with reduced risk of Parkinson's disease in patients with diabetes: a meta-analysis of real-world evidence," is published in the journal Neurological Sciences.

DOI: https://doi.org/10.1007/s10072-020-04494-3